CARGO is advancing a pipeline
of transformational next-generation
CAR T-cell therapies for cancer

3D molecule redering

At CARGO, we are united in our mission to outsmart cancer and deliver more cures for patients. Consistent with our commitment to bring innovative, safe, and effective therapies to patients, we are focused on conducting the clinical trials necessary to gain regulatory approvals to make our cell therapies broadly available to patients. Participation in one of our clinical trials is the best way to access our investigational therapies.

“Expanded Access” is a pathway to use unapproved treatments outside of clinical trials, usually for severe or life-threatening conditions. At this time, CARGO does not have an expanded access program and participation in our clinical study is the only way to access our investigational therapies.

We encourage patients and physicians interested in our investigational therapies to learn more about our ongoing studies by visiting and searching for CARGO Therapeutics (CARGO). If you are a physician who is interested in learning more about our investigational cell therapies or participating in our clinical trials, please submit a request to

This policy may be updated in line with applicable laws and regulations.